A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer [Ann Oncol (2015), 26, 1923-1929]

B. H. O'Neil, A. J. Scott, W. W. Ma, S. J. Cohen, L. Leichman, D. L. Aisner, A. R. Menter, M. A. Tejani, J. K. Cho, J. Granfortuna, L. Coveler, O. O. Olowokure, J. C. Baranda, M. Cusnir, P. Phillip, J. Boles, R. Nazemzadeh, M. Rarick, D. J. Cohen, J. RadfordL. Fehrenbacher, R. Bajaj, V. Bathini, P. Fanta, J. Berlin, A. J. McRee, R. Maguire, F. Wilhelm, M. Maniar, A. Jimeno, C. L. Gomes, W. A. Messersmith

Research output: Contribution to journal › Comment/debate › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer [Ann Oncol (2015), 26, 1923-1929]'. Together they form a unique fingerprint.